Properties (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
Avidity Biosciences
|
| gptkbp:clinicalTrials |
gptkb:Duchenne_muscular_dystrophy
gptkb:MYO-101 MYO-102 Limb-girdle muscular dystrophy |
| gptkbp:collaborations |
gptkb:University_of_Cincinnati
|
| gptkbp:focus |
gene therapy
|
| gptkbp:founded |
2017
|
| gptkbp:founder |
gptkb:Dr._Chris_Garabedian
|
| gptkbp:headquarters |
gptkb:Cincinnati,_Ohio
|
| https://www.w3.org/2000/01/rdf-schema#label |
Myonexus Therapeutics
|
| gptkbp:investmentFocus |
$50 million
|
| gptkbp:mission |
develop treatments for rare muscle diseases
|
| gptkbp:partnerships |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:regulatoryCompliance |
gptkb:FDA_Fast_Track_Designation
FDA_Orphan_Drug_Designation FDA_Rare_Pediatric_Disease_Designation |
| gptkbp:supplyChain |
gptkb:MYO-101
MYO-102 |
| gptkbp:targets |
muscle diseases
|
| gptkbp:technology |
AAV-based gene therapy
|
| gptkbp:website |
www.myonexus.com
|